Literature DB >> 16293849

Adjuvant trastuzumab for breast cancer: assessing HER2/neu status incurs more costs for treatment.

Malcolm R Kell, Colm P Power.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16293849      PMCID： PMC1285108          DOI： 10.1136/bmj.331.7526.1202

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  Adjuvant trastuzumab for breast cancer.

Authors:  Rebecca Dent; Mark Clemons
Journal:  BMJ       Date:  2005-11-05

2.  Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.

Authors:  Michael F Press; Guido Sauter; Leslie Bernstein; Ivonne E Villalobos; Martina Mirlacher; Jian-Yuan Zhou; Rooba Wardeh; Yong-Tian Li; Roberta Guzman; Yanling Ma; Jane Sullivan-Halley; Angela Santiago; Jinha M Park; Alessandro Riva; Dennis J Slamon
Journal:  Clin Cancer Res       Date:  2005-09-15       Impact factor: 12.531

Review 3.  The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.

Authors:  Jeffrey S Ross; Jonathan A Fletcher; Gerald P Linette; James Stec; Edward Clark; Mark Ayers; W Fraser Symmans; Lajos Pusztai; Kenneth J Bloom
Journal:  Oncologist       Date:  2003
  3 in total
  3 in total

1.  Genetic tests and genomic biomarkers: regulation, qualification and validation.

Authors:  Giuseppe Novelli; Cinzia Ciccacci; Paola Borgiani; Marisa Papaluca Amati; Eric Abadie
Journal:  Clin Cases Miner Bone Metab       Date:  2008-05

2.  HER2 testing in the UK: consensus from a national consultation.

Authors:  Mitch Dowsett; A M Hanby; R Laing; R Walker
Journal:  J Clin Pathol       Date:  2007-02-23       Impact factor: 3.411

Review 3.  Current controversies in the management of early breast cancer.

Authors:  L G Estévez; M Martín; E Alba; R Colomer; F Lobo; A Lluch; E Adrover; J Albanell; A Barnadas; J García-Mata; A Llombart; M Muñoz; C Rodríguez; P Sánchez-Rovira; M A Seguí; I Tusquets
Journal:  Clin Transl Oncol       Date:  2007-06       Impact factor: 3.340
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.